Human medicines European public assessment report (EPAR): Lacosamide Accord, lacosamide, Epilepsy, Date of authorisation: 18/09/2017, Revision: 12, Status: Authorised

EMA review of data on paternal exposure to valproate

Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Opioid-Related Disorders, Date of authorisation: 20/11/2018, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Tivicay, dolutegravir, HIV Infections, Date of authorisation: 16/01/2014, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Aimovig, erenumab, Migraine Disorders, Date of authorisation: 26/07/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Deltyba, delamanid, Tuberculosis, Multidrug-Resistant, Date of authorisation: 27/04/2014, Date of refusal: 25/07/2013, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Multiple Sclerosis, Relapsing-Remitting, Date of authorisation: 13/01/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Evenity, romosozumab, Osteoporosis, Date of authorisation: 09/12/2019, Revision: 4, Status: Authorised

Transparency: exceptional measures for COVID-19 medicines

Safety of COVID-19 vaccines